

Letter to Editor: Unilateral Acute Central Serous Chorioretinopathy with Inactivated Coronavirus Disease 2019 Vaccination: A Case Report and Review of Literature

Dear Editor,

We would like to share ideas on the publication “Unilateral acute central serous chorioretinopathy with inactivated Coronavirus Disease 2019 vaccination: A case report and review of literature”.¹ Following vaccination with the inactivated coronavirus disease 2019 (COVID-19) vaccine for coronavirus illness 2019, Abrishami *et al.* found unilateral acute-onset central serous chorioretinopathy (CSC) in a healthy patient.¹ It is suggested that CSC development may be an uncommon but undesirable ocular side effect of the COVID-19 vaccine, according to Abrishami *et al.*¹ Ophthalmologists should be aware of the potential link between COVID-19 immunization and ocular side effects, yet vaccination is the most effective defense against COVID-19, according to Abrishami *et al.*'s conclusion.¹ It is intriguing to wonder if the clinical problem mentioned is connected to the COVID-19 vaccination. Case-specific data may be used in published publications, but the influence of confounding variables cannot be confirmed. Finding the correct response could be difficult. Due to a lack of clinical information on the physiological and immunological status of vaccine recipients before to injection, it may be difficult to pinpoint the precise clinical link, which is an important factor to consider. Comorbidities are rarely mentioned in clinical records, even when they do exist. Determining the precise pathopharmacological relationship can occasionally be difficult because there is limited information available on the health and immunological status of vaccine recipients before injection of the COVID-19 vaccine. It is quite difficult to understand. It can be very difficult to understand how coexisting medical conditions affect clinical results.² The ramifications of genetics are not the least among them.³ The current lack of evidence for any of the findings makes it challenging to identify the specific clinical link.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Rujittika Mungmunpantipantip¹, Viroj Wiwanitkit²

¹Private Academic Consultant, Bangkok, Thailand, ²Department of Biological Science, Joseph Ayo Babalola University, Ikeji-Arakeji, Nigeria

Address for correspondence: Rujittika Mungmunpantipantip, Private Academic Consultant, Bangkok, Thailand. E-mail: rujittika@gmail.com

Submitted: 16-Jan-2023;

Accepted: 29-Jan-2023;

Published: 11-Aug-2023

REFERENCES

1. Abrishami M, Hosseini SM, Shoeibi N, Heidarzadeh HR. Unilateral acute central serous chorioretinopathy with inactivated coronavirus disease 2019 vaccination: A case report and review of literature. *J Curr Ophthalmol* 2022;34:373-8.
2. Mungmunpantipantip R, Wiwanitkit V. Thrombosis after adenovirus-vectored COVID-19 vaccination: A concern on underlying illness. *Clin Appl Thromb Hemost* 2021;27:10760296211060446.
3. Čiučiulkaitė I, Möhlendick B, Thümmeler L, Fisenkei N, Elsner C, Dittmer U, *et al.* GNB3 c. 825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. *Front Genet* 2022;13:932043.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online

Quick Response Code:



Website:

<https://journals.lww.com/joco>

DOI:

10.4103/joco.joco_20_23

How to cite this article: Mungmunpantipantip R, Wiwanitkit V. Letter to editor: Unilateral acute central serous chorioretinopathy with inactivated coronavirus disease 2019 vaccination: A case report and review of literature. *J Curr Ophthalmol* 2023;35:103.

© 2023 Journal of Current Ophthalmology | Published by Wolters Kluwer -Medknow